Sees FY23 SG&A expense $420M-$450M, R&D expense $195M-$220M
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ITCI:
- Intra-Cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance
- Intra-Cellular Therapies to Host Second Quarter 2023 Financial Results Conference Call and Webcast
- Intra-Cellular price target raised to $73 from $70 at Needham
- Intra-Cellular price target raised to $80 from $74 at UBS
- Intra-Cellular Therapies to Present at the Goldman Sachs 44th Annual Global Healthcare Conference